MAYO CLINIC

LifePlus announced clinical validation of LifeLeaf®, the world's first non-invasive wearable for continuous glucose and blood pressure tracking, tested at Mayo Clinic, Cleveland Clinic, and other global centers.

The 2025 European Hematology Association Congress featured promising clinical trial results across multiple hematologic cancers, with novel trispecific and bispecific antibodies showing exceptional response rates in challenging patient populations.

32 Biosciences raised $6 million in funding to advance its AI-powered gut microbiome diagnostic platform and first-of-its-kind non-antibiotic antimicrobial therapy.

Roche's immunotherapy drug Tecentriq combined with chemotherapy reduced cancer recurrence and death by 50% in colon cancer patients with deficient DNA mismatch repair tumors.

Enterome will present positive Phase 2 data for EO2463, its lead OncoMimics immunotherapy, in treating indolent non-Hodgkin lymphoma at the International Conference on Malignant Lymphoma on June 21, 2025.

Pharmacists are uniquely positioned to lead the implementation of advanced cell and gene therapies, serving as both clinical and operational experts in health systems managing these complex treatments.

Mayo Clinic researchers identified that mineralocorticoid receptor proteins clump together during cold storage, causing cardiac damage through increased inflammation and cell death.

The RHONE-X trial demonstrates that faricimab maintains vision improvements and reduced central subfield thickness in diabetic macular edema patients for up to 4 years using a treat-and-extend dosing regimen.

A pharmaceutically manufactured cannabidiol formulation demonstrated a favorable cardiac safety profile in patients with cardiovascular risk factors, according to research presented at Heart Failure 2025.

SeaStar Medical has reached the halfway point in its NEUTRALIZE-AKI pivotal trial, enrolling 100 of the planned 200 adult patients with acute kidney injury requiring continuous renal replacement therapy.